The Role of B Cell and T Cell Glycosylation in Systemic Lupus Erythematosus.
Ivan Emmanuel Ramos-MartínezEdgar G Ramos MartínezMarco CerbónArmando Pérez-TorresLaura Pérez Campos MayoralMaría Teresa Hernández-HuertaMargarito Martínez-CruzAlma Dolores Pérez-SantiagoMarco Antonio Sánchez-MedinaIván Antonio García-MontalvoEdgar Zenteno-GalindoCarlos Alberto Matias-CervantesVíctor Ojeda-MeixueiroEduardo Pérez-Campos MayoralPublished in: International journal of molecular sciences (2023)
Glycosylation is a post-translational modification that affects the stability, structure, antigenicity and charge of proteins. In the immune system, glycosylation is involved in the regulation of ligand-receptor interactions, such as in B-cell and T-cell activating receptors. Alterations in glycosylation have been described in several autoimmune diseases, such as systemic lupus erythematosus (SLE), in which alterations have been found mainly in the glycosylation of B lymphocytes, T lymphocytes and immunoglobulins. In immunoglobulin G of lupus patients, a decrease in galactosylation, sialylation, and nucleotide fucose, as well as an increase in the N -acetylglucosamine bisector, are observed. These changes in glycoisolation affect the interactions of immunoglobulins with Fc receptors and are associated with pericarditis, proteinuria, nephritis, and the presence of antinuclear antibodies. In T cells, alterations have been described in the glycosylation of receptors involved in activation, such as the T cell receptor; these changes affect the affinity with their ligands and modulate the binding to endogenous lectins such as galectins. In T cells from lupus patients, a decrease in galectin 1 binding is observed, which could favor activation and reduce apoptosis. Furthermore, these alterations in glycosylation correlate with disease activity and clinical manifestations, and thus have potential use as biomarkers. In this review, we summarize findings on glycosylation alterations in SLE and how they relate to immune system defects and their clinical manifestations.
Keyphrases
- systemic lupus erythematosus
- disease activity
- rheumatoid arthritis
- end stage renal disease
- rheumatoid arthritis patients
- ankylosing spondylitis
- ejection fraction
- newly diagnosed
- juvenile idiopathic arthritis
- prognostic factors
- peritoneal dialysis
- signaling pathway
- risk assessment
- cell proliferation
- peripheral blood
- mass spectrometry
- dna binding
- human health
- binding protein